Papillomas induced by the cottontail rabbit papillomavirus (CRPV) progress at a high frequency to carcinomas. In this regard, CRPV and its tumors can serve as an animal model for highly oncogenic human papillomaviruses. We have previously shown that immunization with major structural protein Li elicits neutralizing antibodies and protects rabbits from papilloma development (Y.-L. Lin, L. A. Borenstein, R. Selvakumar, R. Ahmed, and F. 0. Wettstein, Virology 187:612-619, 1992). In this study, we demonstrated that vaccination with the TrpE-L1 fusion protein not only protected rabbits from papilloma development but also prevented latent infection. This was indicated by the failure to amplify CRPV sequences by polymerase chain reaction in biopsies from infection sites of immunized animals. Furthermore, we showed that TrpE-L1 immunization protected rabbits from papilloma formation induced by virus but not from that induced by viral DNA. To explore the possibility of developing vaccines based on Li subfragments, we mapped the linear Li epitopes recognized by TrpE-L1-immunized rabbits and by virus-infected rabbits resistant to superinfection. Sera from papilloma-bearing rabbits reacted with one major epitope located at the carboxy-terminal end of Li, between amino acids (aa) 480 and 505. A second epitope, and in some animals a third one, was located in the amino-terminal region, between aa 78 and 101, as well as between aa 37 and 62. Sera from TrpE-Llimmunized animals recognized only one major epitope, located between aa 6 and 37. Immunization of rabbits with Li subfragment fusion proteins led to seroconversion, but no neutralizing antibodies were produced and the animals were not protected against papilloma formation. The data indicate that a successful papillomavirus vaccine must be based on immunization with full-length native Li and that further simplification to smaller peptides containing major linear epitopes is not feasible.
Cottontail rabbit papillomavirus (CRPV) is an animal model for highly oncogenic papillomaviruses (30) . Papillomas can be induced in natural, virus-producing hosts, cottontail rabbits, and with the same efficiency in domestic rabbits. Papillomas on a certain percentage of rabbits spontaneously regress about 3 months after infection. On most rabbits, papillomas persist and in domestic rabbits, especially, a high percentage progress to malignant tumors within 8 to 15 months after infection.
Early studies conducted several decades ago on the virushost interaction provided evidence that antiviral and antitumor immunity is elicited in an infected host (8-11, 16, 18) . Recently, we have conducted a detailed, comprehensive study of the humoral immune response to the two structural proteins and to six nonstructural proteins of the virus in cottontail rabbits at the papilloma stage and in domestic rabbits at different times after infection, including rabbits whose papillomas had regressed or progressed to carcinomas. In both domestic and cottontail rabbits, the most frequent response was to Li, the major structural protein, and linear as well as conformational epitopes were recognized as determined by Western immunoblot analysis or immunoprecipitation (20) . Furthermore, a drastic increase in the response to Li was observed in most rabbits as papillomas progressed to carcinomas.
Immunization of rabbits with Li (19) or L2, a minor structural protein (4, 19) , protected rabbits from papilloma development and elicited neutralizing antibody. Virus neutralization with anti-Li serum was more efficient than that with anti-L2 serum (19) . Immunization of rabbits with a denatured Li fusion protein which contained only the carboxy-terminal (C-terminal) two-thirds of Li, however, failed to protect rabbits (4) . This could indicate that a neutralizing epitope is located in the amino-terminal (N-terminal) segment of Li and that it is possible to generate a protective vaccine consisting only of a segment of Li. Alternately, the conformation of Li may be important in providing protective immunity.
In this investigation, we demonstrated that immunization of rabbits with TrpE-L1 not only protected rabbits from papilloma development but also prevented latent infections. Vaccines consisting of Li subfragments containing the antibody-reactive epitopes or denatured TrpE-Ll, however, did not provide protection, suggesting that conformational epitopes are of primary importance.
MATERUILS AND METHODS
Animals, virus, and sera. Cottontail rabbits obtained from E. Johnson, Rego, Kans., were infected with the Washington B strain of CRPV by intradermal injection (29) , and sera were taken 4 to 6 months after infection at the papilloma stage, as previously described (20) . New Zealand White (NZW) rabbits obtained from Irish Farms (Norco, Calif.) Asp718-digested pATH 20.
b The CRPV sequences cloned extended past the end of ORF Li.
were infected by scarification, and sera were taken at different time points after infection (20) . Fusion protein expression plasmids. TrpE-L1 plasmid LiAccI was previously described (19) . The Li subfragment TrpE fusion protein constructs used are listed in Table 1 . L1-PstI/N, L1-SphI, and L1-BamHI/N were derived from Ll-AccI (the plasmid expressing full-length TrpE-L1) by digestion with PstI, SphI, or BamHI. Each of these enzymes cuts Li-AccI in the Li segment at CRPV nucleotide (nt) 7110 (PstI), nt 7027 (SphI), nt 6358 (BamHI), and at least once downstream of the Li open reading frame (ORF). The DNA segments containing the major portion of the pATH vector and the N-terminal segment of Li were gel purified and religated. Ll-BamHI/C contains the BamHI (6358 to 810) fragment cloned in the BamHI site of pATH22. LiPvuII/N was generated by cloning the PvuII fragment (pATH20 PvuII to CRPV Li PvuII 6292) isolated from Li-AccI into PvuII-digested pATH20. This plasmid contains the Li segment (5843 to 6292). L1/PvuII-PstI and L1-PstI/C were generated by cloning the PvuII (6292)-PstI (7110) or the PstI (7110)-BglII (7661) fragment of CRPV into SmaI-and PstI-digested pATH22 or PstI-and BamHI-digested pATH23, respectively. L1-PstI/C/HaeIII was generated by cloning an HaeIII fragment isolated from L1-PstI/C containing Li sequences from HaeIII (7263) to the end of the ORF (7345) into SmaI-digested pATH23. L1-BN/exo 6132/HinfI and L1-BN/exo 6132/Sau3A were generated by cloning the Hinfl (6042)-ClaI (located in the pATH vector) and Sau3A (6094)-Sau3A (located in the pATH vector) fragments from L1-BamHI/N/exo 6132 into SmaI-and ClaI-cut pATH23 and BamiHI-cut pATH22, respectively.
Exonuclease III and SI nuclease deletion clones. Unidirectional 3'-to-5' deletions were made in L1-PstI/C and LiBamHI/N by using a combination of exonuclease III and Si nuclease digestion by the protocol of Henikoff (12) to determine the end of the deletions. The 3'-to-5' deletion clones were also made from L1-BamHI/N by a method similar to that described above, except that the plasmid was linearized by PstI and BamHI digestion.
Western blot assays. Expression of the fusion proteins in E. coli HB101 was induced with 3-i-indoleacrylic acid by established procedures (17, 28) . The insoluble fractions containing the TrpE fusion proteins (called fusion proteins) were electrophoresed on sodium dodecyl sulfate (SDS)-10% polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membranes (Millipore). The filters were developed with rabbit sera as described previously (18) .
Immunoprecipitation. Immunoprecipitation of Li from extracts of cells infected with Li expressing recombinant vaccinia virus (L1-VV) was carried out as described previously (19 The gels were stained with ethidium bromide and photographed, and Southern blots were prepared and hybridized with a CRPV probe labeled by random priming as previously described (22) . RESULTS PCR analysis of TrpE-L1-immunized rabbits. As previously shown (19) , and shown again here (Tables 2 and 3) , immunization with the TrpE-L1 fusion protein prevents papilloma formation. However, this does not preclude the possibility that a latent infection was established. To determine whether viral DNA persisted at the infection sites, biopsies were taken about 3 months after virus challenge. To permit detection of small amounts of viral DNA, PCR amplification was used with two sets of primers as described in Materials and Methods. One set amplified the CRPV E7 gene and produced a 344-bp DNA fragment; the second set, which served as an internal control for PCR-amplified rabbit cytochrome P-450, form 3a, exon 2 (15), produced a 159-bp DNA fragment. As shown in Fig. 1B from domestic rabbits at the papilloma and carcinoma stages were obtained as previously described (20) . The Western blot of one of the cottontail rabbit sera, K119, with three Li subfragments is shown in Fig. 2 (Fig. 2) . The results for six Li Western blot-positive cottontail rabbit sera are summarized in Table 2 and indicate that multiple epitopes were recognized by half of the cottontail rabbits while one only recognized the N-terminal segment and two only recognized the C-terminal segment. Of four Li Western blot-positive papilloma-bearing domestic rabbits tested, all recognized the N-terminal fragment; one also recognized the middle fragment, and one recognized the C-terminal fragment. Li Western blot-positive sera from domestic rabbits with carcinoma more frequently recognized the middle and C-terminal fragments than did papilloma stage sera. However, there was no qualitative change in Li epitope recognition between the papilloma and carcinoma stages (Table  2) . Finally, the sera from all TrpE-Ll-immunized rabbits recognized only the N-terminal segment of Li (data not shown).
Mapping of the Li C-terminal epitope. To further localize the sequences in the C-terminal fragment of Li recognized by sera from infected rabbits, 3'-5' deletion clones of L1-PstI/C were constructed as described in Materials and Methods. Interestingly, deletion clone Ll-PstI/C/exo 7259, which was only 28 aa shorter than L1-PstI/C, was no longer positive in Western blots (Fig. 3) . To determine whether the entire epitope was contained in the deleted segment, fusion protein plasmid L1-PstI/C/HaeIII was constructed, which expressed only the last 26 aa (aa 480 to 505) of Li. As shown in Fig. 3 , this fusion protein reacted with about the same intensity as the entire C-terminal segment L1-PstI/C. In Fig.  3 , the results obtained with three representative sera from two cottontail rabbits, K119 and K127, and serum from carcinoma-bearing domestic rabbit KWR6 are presented. These sera demonstrate the major pattern of Li C terminus recognition. Although a very weak antibody response to Ll-PstI/C/exo 7259 (aa 428 to 477) was detected in some domestic rabbits (data not shown), only one major epitope in the C terminus of Li was mapped and it is located within the last 26 aa (aa 480-505) of the protein.
Mapping of the Li N-terminal epitopes. The epitopes located in the N-terminal segment of Li were mapped by employing TrpE fusion proteins with increasing deletions at the C-terminal end of the N-terminal segment (aa 6 to 155) of Li and also by using TrpE fusion proteins containing the Li subfragments as shown in Fig. 4 antibody reactivity of about the same intensity as that of the fusion proteins with aa 6 to 101 (Ll-BamHI/N/exo 6132). The results indicate that the Li N-terminal epitope was located between aa 73 and 101 and that aa 90 to 101 did not cover the entire epitope.
The reactivity of some of the domestic rabbit sera was different from that of cottontail rabbits, as shown for NZW5 (Fig. 4C) . The serum reacted with all fusion proteins containing subfragments of the N-terminal segment of Li (Fig.  4C, left panel, lanes 1 to 4) , except the one which contained only the first 37 aa of Li (L1-BamHl/N/exo 5939; lane 5). The reactivity with the fusion proteins containing only the first 62 or 92 aa (Fig. 4C, left panel, lanes 4 and 3) , however, was lower than that of the longer subfragments (Fig. 4C, left  panel, lanes 1 and 2) , suggesting that multiple epitopes were present. This was directly demonstrated by blocking experiments. The fusion protein with aa 6 to 62 not only blocked reactivity to itself but also blocked reactivity to the fusion protein with aa 6 to 92 (Fig. 4C, right The sera of TrpE-L1-immunized rabbits recognized only the N-terminal and not the middle or C-terminal fragment of Li (data not shown). The mapping data for one serum are shown in Fig. 4D . The serum reacted with all subfragment fusion proteins with increasing deletions from the C-terminal end (Fig. 4, left panel, lanes 1 to 5) , including the shortest one, containing only the first 37 aa (L1-BamHl/N/exo 6014). Furthermore, this shortest fusion protein blocked the reactivity of the serum to all longer proteins, indicating that the linear epitope was located between aa 6 and 37 of Li. Overall, cottontail rabbit sera recognized an epitope located between aa 73 and 101, domestic rabbit sera reacted to the same area, and some reacted to an additional epitope located Immunization of rabbits with subfragments of Li. Previously it was shown that rabbits could be protected from papilloma development by vaccination with a TrpE fusion protein containing full-length Li. The presence of a major epitope in the N-terminal segment of Li suggested that this subfragment is also able to protect rabbits against virus challenge. To test this, groups of four rabbits were immunized with full-length TrpE-Ll or subfragment fusion proteins with the N-terminal (Ll-PvuII), the middle (Ll/PvuIIPstI), or the C-terminal (L1-PstI/C) segment of Li or with the parental TrpE crude fusion protein emulsified with the RIBI adjuvant. Two weeks after a second boost, sera were taken and tested for seroconversion. As shown in Fig. SA (Fig. SB) . To test for protection, the rabbits were challenged with CRPV at six sites and scored for papilloma development starting at 21 days postinfection. As shown in Table 3 , only full-length TrpE-L1 protected rabbits from papilloma formation and none of the subfragments or the parental TrpE fusion protein provided any protection. Furthermore, none of the anti-Li subfragment sera neutralized CRPV, as shown in Table 4 . Only hyperimmune serum against full-length TrpE-Li blocked papilloma induction by CRPV, and none of the sera against TrpE-L1 subfragments or the negative controls (no antiserum, preimmune serum, or serum against TrpE) showed any significant effect.
While the Li subfragment fusion proteins left the major linear epitopes intact, it was possible that conformational epitopes, important for protection, were disrupted. To test this possibility, two different subfragment fusion proteins were generated, leaving the junction of the previous set intact. One The presence of well-defined major linear epitopes suggested that a CRPV vaccine based on Li segments containing these epitopes could be developed. In other virus systems, the neutralizing epitopes were mapped to short stretches of peptides (6, 24, 27, 31) and the use of subfragments of viral proteins or synthetic peptides was considered for vaccine development. The test of subfragment vaccines revealed that this was not the case for CRPV. None of the subfragment fusion proteins were able to protect rabbits from CRPV infection, nor did they elicit neutralizing antibodies. Several reasons could account for this outcome. (i) Critical epitopes were located in the junction regions of the subfragments. Since two sets of subfragment fusion proteins were used, the negative results cannot be explained simply by disruption of epitopes at subfragment junctions. (ii) Both B and T cells are required for this protection, and the two cell types may recognize epitopes located in the different segments of Li. However, the fact that rabbits immunized with subfragments did seroconvert suggested that T-helper cells were stimulated and this may have occurred through T-cell epitopes provided by the TrpE portion of the fusion proteins. (iii) Linear epitopes were not sufficient to provide protection, and protective antibodies recognize conformational epitopes. This is supported by the finding that immunization with heat-denatured full-length TrpE-L1 was not protective. The failure of immunization with nondenatured subfragments to provide protection thus suggests that the proper conformation of protective epitopes is maintained only in the context of full-length Li. This provides one interpretation for the inability to protect rabbits immunized with the SDS-PAGE-purified C-terminal two-thirds of Li (4) . Similar results were obtained with BPV-1 (25, 26) . Neutralization of BPV (measured by inhibition of transformation of mouse C127 cells) was observed with antisera against the bacterial fusion protein expressing full-length Li but not with serum raised against an N-or C-terminal subfragment. Results of immunization of calves with a mixture of SDS-PAGE-purified Li N-and C-terminal fragments of BPV-2 (13) are not directly comparable to our results because of differences in the immunization and challenge protocols. In these experiments, the animals were challenged with virus at a time when neutralizing antibody was not detected and animals developed tumors which subsequently regressed. Results obtained with athymic mouse xenographs as a test system for infectivity of HPV-11 showed that neutralizing monoclonal and polyclonal antibodies were directed against external nonlinear epitopes on the virions (2, 3). Thus, with HPV11, as well as with CRPV, neutralizing epitopes are conformational. Overall, our results show that an effective vaccine against papillomavirus infection that prevents tumor formation, as well as latent infections, requires the entire Li protein despite the fact that the major linear B-cell epitopes of the protein were mapped to narrowly defined sequences.
